Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Michael C Kann"'
Autor:
David Millar, Rebecca Larson, Marcela V Maus, Amanda A Bouffard, Matthew J Frigault, Stefanie R Bailey, Mark B Leick, Michael C Kann, Cameron J Turtle, Trisha Berger, Kathleen Gallagher, Korneel Grauwet, Harrison Silva
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Adoptive cell therapy, such as chimeric antigen receptor (CAR)-T cell therapy, has improved patient outcomes for hematological malignancies. Currently, four of the six FDA-approved CAR-T cell products use the FMC63-based αCD19 single-chai
Externí odkaz:
https://doaj.org/article/ecfec6545a5648c1bf0005393d1e6f09
Autor:
Andrea Schmidts, Leah C Marsh, Ambike A Srivastava, Amanda A Bouffard, Angela C Boroughs, Rebecca C Larson, Felipe Bedoya, Bryan D Choi, Stefanie R Bailey, Mark B Leick, Sonika Vatsa, Michael C Kann, Michelle S Prew, Benjamin P Kleinstiver, J Keith Joung
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Adoptive cell therapy with chimeric antigen receptor T cells (CAR-T) has become a standard treatment for patients with certain aggressive B cell malignancies and holds promise to improve the care of patients suffering from numerous other c
Externí odkaz:
https://doaj.org/article/1383b25b9a8e4f49a0640c17e9556951
Autor:
Marcela V. Maus, Matthew J. Frigault, Kathleen M.E. Gallagher, Ashley Demato, Kevin A. Lindell, Harrison Silva, Andrea Schmidts, Marc Wehrli, Mark B. Leick, Trisha R. Berger, Michael C. Kann, Irene Scarfò, Amanda A. Bouffard, Rebecca C. Larson, Sonika Vatsa, Stefanie R. Bailey
Chimeric antigen receptor (CAR) T cells induce impressive responses in patients with hematologic malignancies but can also trigger cytokine release syndrome (CRS), a systemic toxicity caused by activated CAR T cells and innate immune cells. Although
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::304a6031fbfb084825435cf50718e629
https://doi.org/10.1158/2643-3230.c.6550641.v1
https://doi.org/10.1158/2643-3230.c.6550641.v1
Autor:
Marcela V. Maus, Matthew J. Frigault, Kathleen M.E. Gallagher, Ashley Demato, Kevin A. Lindell, Harrison Silva, Andrea Schmidts, Marc Wehrli, Mark B. Leick, Trisha R. Berger, Michael C. Kann, Irene Scarfò, Amanda A. Bouffard, Rebecca C. Larson, Sonika Vatsa, Stefanie R. Bailey
Supplementary Figure from Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa3c245ac8ad9968ea117670a5ca1743
https://doi.org/10.1158/2643-3230.22544430
https://doi.org/10.1158/2643-3230.22544430
Autor:
Marcela V. Maus, Matthew J. Frigault, Kathleen M.E. Gallagher, Ashley Demato, Kevin A. Lindell, Harrison Silva, Andrea Schmidts, Marc Wehrli, Mark B. Leick, Trisha R. Berger, Michael C. Kann, Irene Scarfò, Amanda A. Bouffard, Rebecca C. Larson, Sonika Vatsa, Stefanie R. Bailey
Supplementary Data from Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::892263e8db1e6f8b8ce430812e98389b
https://doi.org/10.1158/2643-3230.22544433
https://doi.org/10.1158/2643-3230.22544433
Autor:
Andrea Schmidts, Ambike A Srivastava, Rishab Ramapriyan, Stefanie R Bailey, Amanda A Bouffard, Daniel P Cahill, Bob S Carter, William T Curry, Gavin P Dunn, Matthew J Frigault, Elizabeth R Gerstner, Jack Y Ghannam, Michael C Kann, Rebecca C Larson, Mark B Leick, Brian V Nahed, Leland G Richardson, Irene Scarfò, Jing Sun, Hiroaki Wakimoto, Marcela V Maus, Bryan D Choi
Publikováno v:
Neuro-Oncology Advances. 5
Background Chimeric antigen receptor (CAR) T cells have achieved remarkable responses in patients with hematological malignancies; however, the potential of this therapeutic platform for solid tumors like glioblastoma (GBM) has been limited, due in l
Autor:
Mark B. Leick, Seunghun Han, Kathleen M.E. Gallagher, Harrison Silva, Grace Martin, Sabrina Camp, Hoyin Chu, Riaz Gillani, Michael C. Kann, Bryan D. Choi, Rebecca Larson, Merle Phillips, Tamina Kienka, Stefanie R. Bailey, Charlotte Graham, Christopher R. Reilly, Max Jan, Elba Gonzalez, Nora K. Horick, Justin Budka, Simone Filosto, Rhine R. Shen, Eliezer Van Allen, Saud H AlDubayan, Marcela V. Maus
Publikováno v:
Blood. 140:646-647
Autor:
Felix Korell, Michael Olson, Diego Salas-Benito, Mark B. Leick, Rebecca C. Larson, Harrison Silva, Alessandro Gasparetto, Trisha R. Berger, Amanda Bouffard, Michael C. Kann, Markus Mergen, Tamina Kienka, Marc Wehrli, Stefanie R. Bailey, Anthony Letai, Marcela V. Maus
Publikováno v:
Cancer Research. 83:4098-4098
Background: Chimeric antigen receptor (CAR) T cells have become a well-established treatment option for patients, with six products approved for different hematologic diseases and new approvals allowing for their therapeutic use as early as second li
Autor:
Stefanie R. Bailey, Sonika Vatsa, Rebecca C. Larson, Amanda A. Bouffard, Irene Scarfò, Michael C. Kann, Trisha R. Berger, Mark B. Leick, Marc Wehrli, Andrea Schmidts, Harrison Silva, Kevin A. Lindell, Ashley Demato, Kathleen M.E. Gallagher, Matthew J. Frigault, Marcela V. Maus
Publikováno v:
Blood Cancer Discov
Chimeric antigen receptor (CAR) T cells induce impressive responses in patients with hematologic malignancies but can also trigger cytokine release syndrome (CRS), a systemic toxicity caused by activated CAR T cells and innate immune cells. Although
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa8be6f624ee9c65eed1694036ba23d9
https://europepmc.org/articles/PMC9414118/
https://europepmc.org/articles/PMC9414118/
Autor:
Mark B. Leick, Harrison Silva, Irene Scarfò, Rebecca Larson, Bryan D. Choi, Amanda A. Bouffard, Kathleen Gallagher, Andrea Schmidts, Stefanie R. Bailey, Michael C. Kann, Max Jan, Marc Wehrli, Korneel Grauwet, Nora Horick, Matthew J. Frigault, Marcela V. Maus
Publikováno v:
Cancer cell. 40(5)
Chimeric antigen receptor (CAR) T cell therapy is effective in lymphoid malignancies, but there has been limited data in myeloid cancers. Here, we start with a CD27-based CAR to target CD70 ("native") in acute myeloid leukemia (AML), and we find mode